- SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
- SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
- SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
- SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
- SpringWorks Therapeutics to Present at Upcoming Investor Conferences
- SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
More ▼
Key statistics
As of last trade SpringWorks Therapeutics Inc (SWTX:NSQ) traded at 39.47, -26.80% below its 52-week high of 53.92, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 41.95 |
---|---|
High | 42.26 |
Low | 38.91 |
Bid | 39.42 |
Offer | 39.48 |
Previous close | 41.46 |
Average volume | 723.12k |
---|---|
Shares outstanding | 74.09m |
Free float | 70.14m |
P/E (TTM) | -- |
Market cap | 3.07bn USD |
EPS (TTM) | -5.15 USD |
Data delayed at least 15 minutes, as of Jun 03 2024 19:35 BST.
More ▼